Show simple item record

dc.contributor.authorColes, Charlotteen
dc.date.accessioned2017-09-05T14:41:58Z
dc.date.available2017-09-05T14:41:58Z
dc.date.issued2017-02-01en
dc.identifier.issn1470-2045
dc.identifier.urihttps://www.repository.cam.ac.uk/handle/1810/267045
dc.description.abstractWhole-breast radiotherapy is the standard of care following breast conservation surgery, but an increasing number of trials are reporting the use of partial breast irradiation for selected patients. In The Lancet Oncology, Csaba Polgár and colleagues1 present the results of the Groupe Européen de Curiethérapie European Society for Radiotherapy and Oncology (GEC-ESTRO) trial of accelerated partial breast irradiation (APBI), whereby patients were randomly assigned to whole-breast irradiation in 2 Gy fractions for 6 weeks up to a total dose of 50 Gy, or APBI using brachytherapy, typically given in seven or eight fractions over 4–5 days.
dc.description.sponsorshipI am supported by the Cambridge National Institute of Health Research Biomedical Research Centre.
dc.language.isoenen
dc.publisherElsevier
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
dc.titleAnother piece in the jigsaw of accelerated partial breast irradiationen
dc.typeArticle
prism.endingPage169
prism.issueIdentifier2en
prism.publicationDate2017en
prism.publicationNameThe Lancet Oncologyen
prism.startingPage168
prism.volume18en
dc.identifier.doi10.17863/CAM.13074
dcterms.dateAccepted2016-11-04en
rioxxterms.versionofrecord10.1016/S1470-2045(17)30001-3en
rioxxterms.versionAMen
rioxxterms.licenseref.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/en
rioxxterms.licenseref.startdate2017-02-01en
dc.contributor.orcidColes, Charlotte [0000-0003-4473-8552]
dc.identifier.eissn1474-5488
rioxxterms.typeJournal Article/Reviewen
cam.issuedOnline2017-01-13en
rioxxterms.freetoread.startdate2017-07-13


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 International
Except where otherwise noted, this item's licence is described as Attribution-NonCommercial-NoDerivatives 4.0 International